Is Gastroparesis a Side Effect of Ozempic?

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists have transformed weight loss treatment, but questions about digestive side effects persist. Gastroparesis, medically defined as delayed gastric emptying without mechanical obstruction, has been reported in some patients taking semaglutide and tirzepatide—though the actual incidence remains low. PlexusDx helps patients understand this risk and select the right medication based on their genetic predispositions.

What Is Gastroparesis and How Does It Relate to GLP-1 Medications?

Gastroparesis occurs when the stomach takes longer than normal to move food into the small intestine. The condition can cause nausea, vomiting, bloating, and early fullness. GLP-1 medications like Ozempic work by slowing gastric motility as part of their appetite-suppression mechanism, which raises the theoretical risk of delayed emptying in susceptible individuals.

The FDA has not classified gastroparesis as a formal black-box warning for GLP-1 drugs, and large clinical trials show it remains uncommon. However, case reports and post-market surveillance have documented instances, particularly in patients with pre-existing risk factors. Understanding your personal risk profile—through genetics and medical history—helps inform the safest weight loss approach.

Risk Factors and Who Is Most Vulnerable to GLP-1–Related Gastroparesis

Patients with a history of diabetes, especially those with long-standing type 2 disease, may have subclinical neuropathy that already affects stomach nerve function. Rapid dose escalation, female sex, and older age have been flagged as additional risk markers in case reports. Genetic variants affecting peptide signaling pathways—such as those mapped by PlexusDx's Precision Peptide Genetic Test—can influence how your body responds to GLP-1 stimulation.

The Precision Peptide Genetic Test examines variants in genes including GIPR (rs1800437), and MC4R (rs17782313), which control how your cells respond to these medications. Identifying protective or risk-associated variants across 14 metabolic pathways and 49 peptides allows PlexusDx to recommend the safest compound, dose strategy, and monitoring plan for your unique biology.

Symptoms of Gastroparesis: When to Seek Medical Attention

Classic symptoms include persistent nausea unrelated to hunger, vomiting shortly after meals, bloating that worsens as the day progresses, and feeling full after eating small amounts of food. Some patients report abdominal discomfort or unintended weight loss despite adequate calorie intake. If these symptoms emerge after starting a GLP-1 medication and persist beyond the first 2–4 weeks of adaptation, medical evaluation is warranted.

PlexusDx recommends contacting your prescribing physician immediately if you develop severe abdominal pain, frequent vomiting, or signs of dehydration. A gastroenterologist can perform a gastric emptying study (scintigraphy) or wireless capsule test to confirm the diagnosis. In the vast majority of cases, dose reduction or temporary pause of the medication resolves symptoms; switching to an oral formulation or a different compound may also be considered.

How PlexusDx Personalizes GLP-1 Selection to Minimize Gastroparesis Risk

PlexusDx offers both injectable and oral semaglutide and tirzepatide formulations, allowing flexibility if one route causes digestive distress. Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), while Oral Semaglutide is $289/mo month-to-month, or from $249/mo on the 6-month plan—your dose may need to go up, but your price won't. The Microdose GLP-1 Protocol at $129 per month is another option for patients preferring a gentler initiation.

Adding the Precision Peptide Genetic Test ($298) reveals your individual peptide-pathway profile, helping prescribers tailor dosing schedules and compound selection. Patients with genetic predispositions toward slower gastric adaptation may benefit from slower titration, microdose protocols, or oral formulations that bypass some gut-mediated effects. All PlexusDx medications come from licensed 503A compounding pharmacies, are available in all 50 states without insurance, and are HSA/FSA eligible.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the actual rate of gastroparesis in people taking Ozempic?

Large clinical trials report gastroparesis incidence below 1% with semaglutide, though post-market case reports suggest it may occur more often in real-world use. The true frequency remains unclear because mild or transient cases may go unreported. PlexusDx genetic testing helps identify who is at higher risk so preventive strategies can be put in place early.

Can gastroparesis from GLP-1 medication be reversed?

Yes, in most reported cases, symptoms resolve within days to weeks of dose reduction or medication discontinuation. Some patients tolerate the medication again after a break or dose reset. If gastroparesis persists after stopping GLP-1 therapy, underlying nerve damage must be evaluated by a gastroenterologist.

Is oral semaglutide safer than injectable semaglutide for gastroparesis risk?

Oral semaglutide may pose lower risk because it bypasses direct gastric stimulation, though both formulations activate GLP-1 receptors systemically. PlexusDx offers Oral Semaglutide at $289/mo (or $249/mo on the 6-month plan) as an option for patients concerned about injection-related gastric effects. Your prescriber can help determine which route suits your medical history best.

Should I avoid GLP-1 medications entirely if I have diabetes?

No. While diabetes is a risk factor, the vast majority of diabetic patients tolerate GLP-1 therapy without gastroparesis. A careful dosing plan, genetic testing via the Precision Peptide Genetic Test, and close monitoring can safely enable weight loss and glycemic control. Discuss your specific diabetes history and symptoms with your PlexusDx provider.

How does the PlexusDx Precision Peptide Genetic Test help prevent gastroparesis?

The test identifies genetic variants in GIPR and MC4R, and FTO genes that influence how your digestive system responds to GLP-1 stimulation. Understanding these variants helps PlexusDx prescribers design a personalized dosing schedule and select the safest compound—reducing the risk of adverse gastric effects before they develop.

Related Reading

• Ozempic Side Effects
• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.